India’s pharmaceutical sector is urged to make bold investments and embrace innovation for future growth, experts highlighted at the ‘India Pharma 2026’ event in New Delhi. The event, jointly organized by the Department of Pharmaceuticals, FICCI, and IPA, saw over 800 delegates and 60 speakers participating in discussions over two days. Satyaprakash TL, from the Department of Pharmaceuticals, emphasized the importance of funding, infrastructure, and speed for the sector’s advancement.
Discussions at the event underscored the need for collaborative efforts among the government, industry, and academia to propel India as a global leader in pharmaceuticals. Stakeholders stressed the significance of coordinated action to navigate the evolving global pharmaceutical landscape effectively. Dr. Shivkumar Kalyanaraman of ANRF highlighted the importance of diverse financing mechanisms, including venture capital and public-private partnerships, for sustained sectoral growth.
The event also delved into the necessity of innovation-driven transformation for India’s pharmaceutical sector to achieve significant progress. Winselow Tucker, from Eli Lilly India, emphasized the need for a strategic roadmap with clear milestones to drive successful transformation in the industry. The discussions aimed at steering India towards a future marked by innovation and bold initiatives in pharmaceuticals.
